Baird Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Jeff Johnson has maintained a Neutral rating on Tandem Diabetes Care (NASDAQ:TNDM) and increased the price target from $28 to $36.
May 03, 2024 | 11:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Jeff Johnson maintains a Neutral rating on Tandem Diabetes Care but raises the price target from $28 to $36.
The increase in price target from $28 to $36 by Baird indicates a positive outlook on the stock's value, potentially leading to increased investor interest and a short-term positive impact on TNDM's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100